REG - Hutchmed China Ltd - Extraordinary General Meeting – Poll Results

HUTCHMED (China)Announcement

31/03/2025 10:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250331:nRSe9079Ca&default-theme=true

RNS Number : 9079C  Hutchmed (China) Limited  31 March 2025

 

 

Extraordinary General Meeting held on March 31, 2025 ¡V Poll Results

 

 

Hong Kong, Shanghai, & Florham Park, NJ: Monday, March 31, 2025: HUTCHMED
(China) Limited (¡§HUTCHMED (https://www.hutch-med.com/) ¡¨ or the
¡§Company¡¨) (Nasdaq/AIM: HCM; HKEX:13) today announces that the ordinary
resolution put to its Extraordinary General Meeting (¡§EGM¡¨) held on
March 31, 2025 was duly passed.

 

Reference is made to the notice of EGM dated March 14, 2025 and the circular
to shareholders dated March 14, 2025 (the ¡§Circular¡¨) issued by the
Company. Unless otherwise defined herein, capitalized terms used in this
announcement shall have the same meanings as those defined in the Circular.

 

The poll results of the ordinary resolution were as follows:

 

 

                                                                                  Number of Votes (%)*

                                                                                                                         Passed by Shareholders

 Ordinary Resolution

                                                                                  For          Against     Withheld(#)

 To approve the transactions related to the sale and purchase of a total of 45%   475,229,253  121,270     1,670         Yes
 equity interest in Shanghai Hutchison Pharmaceuticals Limited under various

 agreements, and all actions by the Company and/or its subsidiaries pursuant or   (99.9745%)   (0.0255%)
 incidental to such transactions.^

 

*  Percentages rounded to 4 decimal places.

(#) A vote withheld is not a vote in law and is not counted in the calculation
of the proportion of the votes for or against a resolution.

^ The full text of the resolution is set out in the notice of EGM dated March
14, 2025.

 

Notes:

 

(1)       Except for Ms Ling YANG who had prior overseas commitments and
was unable to attend the EGM, all directors of the Company, namely Dr Dan
ELDAR, Dr Weiguo SU, Mr CHENG Chig Fung, Johnny, Ms Edith SHIH, Mr Paul
Rutherford CARTER, Dr Renu BHATIA, Dr Chaohong HU, Mr Graeme Allan JACK,
Professor MOK Shu Kam, Tony and Mr WONG Tak Wai, attended the EGM, either in
person or by means of electronic facilities.

 

(2)       Number of shares entitling the holders to attend and vote on
the resolution at the EGM: 871,601,095 shares.

 

(3)       Number of shares entitling the holders to attend and abstain
from voting in favor as set out in Rule 13.40 of the Rules Governing the
Listing of Securities on The Stock Exchange of Hong Kong Limited (the
¡§Listing Rules¡¨) at the EGM: Nil.

 

(4)       Number of shares for holders required under the Listing Rules
to abstain from voting at the EGM: Nil.

 

(5)       The scrutineer for the poll at the EGM was Computershare
Investor Services (Jersey) Limited, the Principal Share Registrar of the
Company.

 

 

About HUTCHMED

 

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage,
biopharmaceutical company. Іt is committed to the discovery, global
development and commercialization of targeted therapies and immunotherapies
for the treatment of cancer and immunological diseases. Since inception it has
focused on bringing drug candidates from in-house discovery to patients around
the world, with its first three medicines marketed in China, and the first of
which is also approved around the world including in the US, Europe and Japan.
For more information, please visit: www.hutch‑med.com
(https://www.hutch-med.com/) or follow us on LinkedIn
(https://www.linkedin.com/company/hutchmed/) .

 

 

 

 

 

 

 

 

 

 

 

 

CONTACTS

 

 Investor Enquiries                                   +852 2121 8200 /

                                                    ir@hutch-med.com (mailto:ir@hutch-med.com)

 Media Enquiries
 FTI Consulting ¡V                                    +44 20 3727 1030 / HUTCHMED@fticonsulting.com
                                                      (mailto:HUTCHMED@fticonsulting.com)
 Ben Atwell / Alex Shaw                                   +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)
 Brunswick ¡V Zhou Yi                                 +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
                                                      (mailto:HUTCHMED@brunswickgroup.com)

 Panmure Liberum                                      Nominated Advisor and Joint Broker
 Atholl Tweedie / Freddy Crossley / Rupert Dearden    +44 20 7886 2500

 HSBC                                                 Joint Broker
 Simon Alexander / Alina Vaskina / Arnav Kapoor       +44 20 7991 8888

 Cavendish                                            Joint Broker
 Geoff Nash / Nigel Birks                             +44 20 7220 0500

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROMPKDBQFBKKPNN